TCRT - Earnings call transcript Q2 2022 | Alaunos Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Alaunos Therapeutics' Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference maybe recorded. I will like to hand the conference over to your speaker today, Danielle Dudgeon, with Stern Investor Relations. ahead. go Please

Danielle Dudgeon

Vice XX, welcome Mike results and on XXXX. results is press today Therapeutics press ended at one available quarter June report Earlier of Alaunos Drew encourage for second Kevin the everyone Abhishek morning, and Good Vice as SEC. today's this Web ended for Alaunos' XXXX, filed Vice Srivastava, call the to announcing three quarter President read We release, and the release financial President Deniger, quarterly Officer; with will Executive conference Senior, Operations; the The me to a of months audio XXXX also which financial the Research morning XX, Boyle Alaunos.com. site June Development; Alaunos Form company's be and morning, Technical well this and Chief as Alaunos President Wong, press webcast. issued are Finance. quarterly report XX-Q With of release

In of be like is addition, potential uncertainties in the harbor business. materially could made risks of live and forward-looking that are statements Participants forward-looking except on company's time-sensitive results this to or certain date call no recent webcast risks to stated or revise discussed site, to through conference the as would company's any broadcast, ec.gov. undertakes under Act by information only law. Actual on the said, filings future by call company may to our August public Web those of With XXXX. the differ webcast, be most and conference that the section of with as Securities this update forth will with call Kevin being SEC Investor information Reform uncertainties The are and or Relations implied Private set the of contains Litigation provisions over Information this XX, the XXXX. circumstances there associated applicable cautioned that to from due the Please note of for is securities I today's reference. after that reflect Boyle. call safe covered date archived at this is the today turn events the accurate required statements obligation

Kevin Boyle

having the time Thanks, Danielle. Welcome voice in Good the teacher, my strong one-year the the just to quarter been and time I are earnings Latin grade you're the that's made team has clinical operational, of I of remember year. over fun. back and manufacturing, formed morning, seventh our the for when flies. a anniversary hit past rebuild everyone. call. And second foundation joining to Apologies and XXXX team. Alaunos approach flies I'm Rossi, dedicated so I tempus company, by The progress and fugit, here, my eighth phrase, Mr. proud frog

to Library with Phase X/X level I'm board. our very this as expand future to to manufacturing are same clinical working the and to pleased our say actively TCR-T At capacity expansion, lead dose we're investigators effort. welcome safety enroll, of we're Our President that ahead after and pleased to Operations, second continuing time, moving support Technical to at Vice the consulting trial review Abhi, is and

team expand the together and to training offers. and excited I on just at to the wanted as will but it seek we and to You optimize manufacturing our the worked Small world couple minutes, him Abhi that are Abhi hear beneficiaries of NCI, in both have from of that world-class very say capabilities. a Drew we're

bile in successful with mind collaboration, right Rosenberg the cancer into targeting using for XXXX, cancer Library extend and across TCR-T partnership mutations indications; lung, endometrium, it's tumors. our non-small our team X/X R&D platform. a privileged ovary, X/X cell with patients to and working the to duct most we proof Rosenberg's tumor very continuing combined trial an NCI long-term TCR-T provide importantly reminder, our of expertise, therapies cell we the This Phase improve team, novel on the as different generating pancreas, to efforts, this develop In hotspot and solid our Alaunos have with trial, in Library with a quarter, lives six believe we TCR-T we concept the to look CRADA Phase approach. Dr. basket right And right are and my in approach, our personalized colorectal, of the to When that the Alaunos personalized cancers. solid forward and Dr. be update trial,

down enrolling EGFR. Cancer which based consists street, of Center, that currently XX one of TPXX, cancers these with mutation Anderson library, HLA MD in one patients are pairings we available We the five matching on at our are KRAS, and have four six TCR-T TCRs;

patient recall, dosed billion patient non-small with the targeting cells this trial, own May, first treated may level manufactured KRAS lung five This you dose approximately cell announced the in and our mutation. TCR-T very cGMP a or GXXD that was we cells. patient X we in-house the driver As at facility. has mutation, in TCR-T in The

TCRs institutions. Medicine, dose even approach mutations an two medical of in Cancer look leading was quarter data in published England meeting more the TCR-T let TPXX confidence with were recent papers forward go Anderson, in have treated safety TCR-T be our we the by into XX findings in well clinical to level MD Research. investigators early Journal of using moving second our TCR-T using with our in highlight but One approximately mutations and that look a cells in target these ahead detail in progress greater instilling with discussion Immunology with as to to New by case we that believe academic and cells. KRAS the at the third data the library. published of we're studies in very resulted right the about papers, other remain like at as we're billion of I'd durable the cells hotspot to the at Following responses on year. these We pleased providing review Drew encouraged And but a this trial, and I'll patients track, of

we in Now, have more we're a we better believe and Beauty and approach clinical cost-effective testing that commercially scalable TCRs trial. Sleeping proprietary our these technology, using actively our

to a prepared, capabilities. as like strategy the on working diligently execute manufacturing scout old to Now, motto, be expand multi-pronged to our much we're

long-term sufficient our membrane-bound R&D at expansion in pipeline. this expand IL-XX, we have our we effort while for capacity Now, future to the believe will as next and continue our with least year, us X/X well the study we Phase support clinical serve

our will implementing SOPs products. cGMP we're of First, that work our suite. new for And includes further multiple also this manufacturing process cryopreserved optimize products simultaneous in to production by cell allow introducing

lastly, continuing additional built will capability. increased the support GMP need footprint already expanding And having to hire cGMP are to one suite, we arises. as manufacturing staff we Secondly, successfully investigate physically our

darinaparsin, turn worldwide Pharma. XXXX, formed as over our Darvias. to and known briefly to I touch granted an R&D Solasia upon exclusive that license was call way collaboration have collaboration the before Drew highlight with commercialize back initially also efforts, we agreement This in to develop Now, and a Solasia to I wanted

percentage this by sub-license Solasia. As are license of revenue any we sales-based and eligible part of a agreement, generated milestones for cash

Japan. a be manufacturing continue Health, we're commercialization. that has related to excited refractory And will Now, XXXX, Solasia June In peripheral and in been for them. for of Darvias responsible significant all and the relapsed Welfare, represents to at T-cell lymphoma Solasia Labor, of this costs for their approved team by announced or as for milestone Solasia Ministry

we expand to own these but going development not further for support our will receive Now, internal to now over program. royalties on call the the with were I'm the hand help to academic NCI, sales, Rosenberg to that non-dilutive continued significant papers and to additional capital recently Drew certainly those published. do expect highlight supportive capital on Dr. and the Drew? our partnership also

Drew Deniger

Kevin's like Kevin. to echo sentiment. I'd you, Thank

targeting England with and study of only objective the one six follow-up. their research paper have benefits of response who KRASGXXD showed innovative with in Alaunos clear clinical of of I development TCR-T with reduction hotspot at article hotspot validate also to by am Journal HLAs transform thrilled one the The compared clinic. TCRs an infusion. therapy. to months of post and frequent the cancer in XX% target help research XXXX. specific with Our team was into we've contributed clinical immunology mutations, worked cancer article power mutations patient and to was of articles cancer, with This approach and its cells validate This TIL tumor New to TCR-T greater Medicine the treated TPXX targeting of advanced highlighted cancer potential. which HLA-AXX, a that library cells for to TPXX immunology most The of our case than is partial KRAS mutations that research United an targeting confidence The our further the and pancreatic the led TCRs Both TCR-T. the showed publications tumors that approach breast Institute shared skin these meaningful in TXX has research days ongoing including most publication recent is common our the our of to extended progress achieved corporative in company XX% mutations. great States, National agreement regression Cancer resolution XX New that Journal mutation. England significant a

advanced has to Rosenberg for cells with successful NCI the technology. TCR-T continue Sleeping ability mentorship transfer data the presented I of tumors non-overlapping therapies work help of the ASGCT bring therapy to and many that proprietary together lucky cells. TCR-T work we vision to on to program. patients And the autologous data with personalized technologies. effective parties our that our membrane bring is cell the Beauty Dr. personalized believe together. to believe strongly while our in advantages under IL-XX significant have TCR-T amended touch TCR-T clear that In will CRTA. specifically bound Rosenberg, fully we the application using And bound would of commercial cancers. kill May, TCR-T I immunotherapies like long-lived work to honored the in pioneer to non-viral Beauty Dr. specific asset, membrane cell work also fundamental personalized was setting. new therapies Under developing the target to the potential believe Both cell enough also tumor follow-on generate this briefly for IL-XX we are proof-of-concept Sleeping be I will highlighted development CRTA, and gene our for the privilege competing of establishing ideal expertise years. to at will We for We a

the has responses. program find data persistence to these and potential website. We can believe this deepen You our cells clinical TCR-T increase on the that of

We to this are IND second-half program an of continuing advance the XXXX. towards in filing

TCRs. Lastly, program the of TCRs. using our to these we to platform decrease further library discover infrastructure addressable continue our the We TCR-T hunTR increase on make progress for our are building we And to cost increase significant throughput and aim market to proprietary screening. using

team capital. the occurred turn update financial to I the Wong call has detailed last year. results already existing the the to add hunTR for to would second to like Mike We create to non-dilutive anticipate generating the the more trial the to ability quarter. program Our TCRs Furthermore, to TCRs on clinical fourth a sharing hunTR potential in over that parallel review quarter. demonstrated the now with the Mike? licensing has in opportunities the amendment

Mike Wong

you, Drew. Thank

our the for ended three XXXX. XX, June financials month me Let review

approximately employee compared of expenses. the million third the services to reduced of XXXX, $X.X primarily $X.X quarter in XX%. of headcount decrease on approximately platform. quarter decrease cost lower to quarter to $XX.X net decrease expenses. third The decrease net our as our period XXXX. or expenses Research professional a of quarter a approximately restructuring of decrease expenses XXXX $X.XX quarter for per the in and million second related in loss $X.X in was million A and consulting loss focus due of for expenses employee of following a Administrative For $XX.X million consulting loss the approximately XXXX, share, the our loss to was quarter were second And primarily in second the quarter XX%. for to approximately lower due due XXXX, XXXX, our approximately $X second the per The million XXXX. we a restructuring the $X.X expenses to of were net a same second of of following $X.X or net due million $X.XX General of the headcount million decrease $X.X $X.X for the related for a a million of million XXXX in Development TCR-T related of reported $X.X and million compared decrease compared and share million reduced program

As XX, XXXX. cash runway sufficient cash and second Alaunos cash operations million in anticipate of quarter into June $XX to of our XXXX, had equivalents. approximately the fund to We be

cash for XXXX was concludes I like to second call million $X.X XX%. burn the quarter million, $XX.X now to of decrease turn compared the Our Kevin. operating or of would XXXX, the in quarter second update. That of a million our financial $XX.X to

Kevin Boyle

you, Thank Mike.

we our update, remained behalf shareholders. heard you financial steward of in that Now on good capital of

was expenses the our on reducing our expenses focused of do. And all singular it over substantial have that cash right thing to this thing TCR-T progress We tumors. XX%. end were the in lives with with by into trimming the trimming were through improving cancer do. to and burn despite advance patients because year solid made are was advancing we our goal before activities clinic We We it platform past programs of

at a Development process where Professor previously, Assistant the Therapy Srivastava, development he over led And Cell you to he turn like Operations. TILs. we to and of the Technical say was President of would I newest Abhishek was words? our University recently introduce of most Before call like member manufacturing Vice at of Pittsburgh, to Vice Abhi, few questions, of Abhi President would team, the Athenex. our the

Abhishek Srivastava

really technology. when Kevin. very this at It I me NCI excited my as reminds old am working Thanks, join Alaunos. a fellow to was days associated And I with and

the really my is in science really truly truly capability would this technology to excited I in and who part I believe advance this support And really to the are enhancement really this to this, this manufacturing team With and of need. be who bringing So, really patients Kevin. product this ready drive development treat am to background, to I believe team in technology. With and manufacturing I am that provide handover technology. so

Kevin Boyle

have to you here. great Abhi,

you part We team. of are excited to have the as

manufacturing we working diligently So, multi-pronged expand execute of with are appointment the Abhi, to against to strategy capacity. our

will Abhi So, Day do. that one plenty successful. And walked he we and confidence be to has he in have great

support dedicated our shareholders across and I investigators, strides our to entire appreciate So, as make employees, patients, continue we MD of business. our great Anderson all Alaunos the for their

and we additional early for working a As scientific at third trial the we conference. second-half year, the our quarter prepare of the are X/X data in patients the to to present consent trial enroll from Phase plan in and

of the solid cell program We to as On again well the tumor patients we continue membrane we the you approach our updating suffering move a personalized mission to filling with continue therapy IND lives to cancers. an front, excited forward soon IL-XX improve TCR-T bound to advance NCI as towards are XXXX. of as our R&D second-half in look from

Michelle? open call will questions. now We to the

Operator

question Instructions] line comes Thank Agrawal Fitzgerald. first from Prakhar with the Our of Cantor you. [Operator

is open. Please line Your ahead. go

Prakhar Agrawal

morning, my questions, the progress. Hi, all Thanks on congrats everyone. for good and taking the

for expect if be dosed expectations maybe QX? at maybe you data will on you many clarify, the What and patient being can on So, bar or should update identified? we and team you? has can the Kevin you. presented set patients first And comment second what's and question, in how if this Thank

Kevin Boyle

with be we'll we'll it's data, second-half be we some we'll medical the weeks stay nice that, conferences tuned. what, not able presenting a be of quarter, data morning, this so of to year the hope be the doing good a just and presenting the that in locator-only some scientific about meeting been Prakhar, trial. third Only, of in information news there as or well, you so in the are share We're to information to that the more presented, more very are but, but Because of on that at considerate I'm be excited you validation please the as We board glad not share and what say that our at about much our allowed to and in so not six as is kind and want indeed, situation too. welcome received giving of of way We want patients do are will trial. not restrictions that. in the review But the we a here, get safety to promise by I regards encouraged updated, whether number what treated will interested quarter forth second the of we're we we dose patient, and where excited And a us be front. second in level. investigators to progress with or seeing have put we'll encouraged left that again, we've to patient-by-patient tuned that out. we're stay

you we some but questions look the next to receiving you as forward Thank have information answer and So, the six it, again, so point look that the we'll weeks sharing as in much time, there. we'll to do at you. forward

Prakhar Agrawal

Kevin. Thanks,

Operator

the And comes with from our next question Lake Markets. of Capital Street Thomas line Flaten

open, is line please Your ahead. go

Thomas Flaten

thanks that been TCRs questions. the wondering an to and on has number and taking been rate Kevin, what the give the library. the in us screened for match you I update morning, Good was the could patients have of total if

Kevin Boyle

Sure. morning, Good Thomas.

patients XXX that we we rate efficient, seeing. screening, number patients we a match continue And treatment the screened that alone, of are are the to We very their the screened patients and very following means funnel with on over or that of journey. There's so by so to we're have be pleased we patients, continue patients the get to identifying we pipeline, cost-effective number and increase lung two over the patients. XXX prospective indications between is colorectal and those X%, over

how over thing Thomas, So, adding library, other since as gathering well. either the insert expand we'll TCRs highlight and library information mutations lung, we're we our the Hunter of with be addressable to we pleased we -- these that and we're that's anticipate And to increase moving fully to the as that up progressing be the increase add in to HLAs. new that our is we'll we TCRs with as market, be patients colorectal patients to have TCRs we platform TCRs, all have our new XXX new pick that will very that or here, able forward, able new

very of continue enrollment able going trial. we're this pace on we're to a encouraged to So, nice be that

Thomas Flaten

Fantastic. wondering salvage characterize the And information might you then started be have being coming second-line are that screened of just I you MD able typically are and patients have or just that maybe qualitative that? around some was third-line if you Anderson, it is patients, to seeing patients if folks by at the curious types some

Kevin Boyle

It's great see question. a We it all.

have are diagnosed cancer a patients and in state as of time, or health see out the for of result, noticed these just from we And treatment MD centers Sometimes may just and the were and patients one Anderson best to of a world. going in size. walking are unfortunately scare the maybe first came recently all

this patient recently And Sometimes because that -- care patients the might these sometimes have need. we're a that's they to in diagnosed. been the honest, a let's be and that patients can last why, while make get sure all journey be

But and in their encouraged extend frontline we of make patients means not our ability quality our that the hope working plan, and therapies if and taking, difference science human to are trial for is case their the treatment that's if, I never to technology, says, improve a these of life life. therapies So, there -- very me about and see because unfortunately, frontline in a on their there's they're the I then much really side them. the are failure that and

working. So, trial, other our all getting stages, at because end might take little immediately some be trial we never some might ready our a some see therapies patients might all to join are longer, up

depends as indication worthy the The is nothing of other on it well. thing

much other So, again, some there treatments them indications Hopefully line, it's well. indication-specific very that -- as and or therapies be earlier might So, more approved indications we in might for be

Thomas Flaten

much so for thanks great, questions. the that's Yes, taking that. Appreciate

Kevin Boyle

pleasure. My you. Thank

Operator

question Company. Laidlaw from Yale next line comes the with our Jen And of &

ahead. Your line is open, go please

Yale Jen

roughly Good that my of and follow to math is My taking previous morning, might maybe screened matched, on one thanks numbers based for the question, have you the there and correct. XX if the the patients questions.

the capability can manufacturer capacity gating or how other factor will things treatments? Just for many or patients curious or whether -- that much dictates be factor -- you the limiting one -- that how for process of start

Kevin Boyle

Yale, getting the thanks good factor is for again, and why, manufacturing, morning, ahead in of not that's question. the rate The limiting the curve. we're and near-term

we're optimization. the ahead investing having community. ahead is we're prepared, that's, As and come onboard, him investment manufacturing about to I why for future forward the look broader to But excited following scout expansion, old of, planning Abhi working have said, motto be so for start indeed, his planning on meet background to

As the we time, do stage. in able ready now, patient ways also clinical for shy increase the optimize well treatment certainly little working and too, that's for that manufacturing reduce find know by and to our the nature, step. reduce our fine early the it so I throughput process are itself, not for does That help perhaps have in But, that's when days, right is progress forward produce manufacturing. trial. XX this a we cryopreservation, that in And being rate-limiting this that'll of to to to suite. of want to of continuing we point, on But cells will at development look with highlight that that our working GMP a manufacturing is process and we is as to

Yale Jen

patient study? more to dosed move the lastly the little could And dictates [measures] X/X second anticipated -- that you rapidly, total give that can of color this to what Okay, doses? Phase more [Ph] factors you follow-up dose here And bit move the is great, be us given a you the is for second could that, what thanks. are very to And that's helpful. the one question -- the question maybe what's that or

Kevin Boyle

Yale. Thanks,

So, me few a on things. touch let

are the patient We did, the we moving we surprised but That's level. why that as not are dose designed to second design. trial we encouraged with this

approach So, And the cells, to targeting that's hotspot in only on what that's tumor tissues, us, nowhere an mutations start part, at reminder, level. believe, companies because TCR superior as our to a we is and appear healthy allowed these reminder. in other a mutations, dose higher important these

So, literature a dose level very was already based efficacious broad done the dose cells. at X levels review X TCR-T team, that billion on begin by

new at And a so, then billion safety is Phase important trial we're fact dose X the identify these and throwaway thrive. the that survive, But X starting the TCR-T are to And cells, because causing the very only encouraged thing. tumor again, level. want first the appear recommended things Phase these what's the causing we're X at foremost we not in mutations starting in we're a that tumor, targeting to most to hotspot tumor we Absolutely, dose. antigens, what's

we're so kill and that identify we're is driving them because a after can the doing honing target the cancer; of and so, our going manner not to it's fact in the TCRs kind tissue. any right healthy what And safe very

I that just so, stress can't And enough.

our at were was assessed good, looked it indicate treated. of the the that call investigators And profile and on prior patient. or be very difficulty] from patients that a the and So, the first is looking by patient we after first and safety the by going reviewed the to did that review data board safety patient [technical

by pleased the and the again, talk patient. we And safety very So, are that as determine the patient be first the we infusion with first safety in days treated. for review each to safety that profile about every we before board appropriate the did evalued is it XX saw investigators and the dose responses the is say after that we our in next that that time and and

Yale Jen

the be of or will patient the planned study? numbers for total you Phase X/X expected what And

Kevin Boyle

let to Yale. going us, tell the We're science

X with indications patients into evaluate as to the decide trial will the Phase have the to open a things dosed the and statistics as and let different we locked the they design. help get treat. as predescribed various Phase while various And having So, well, the a part number design in ability the We're X/X appropriate is trial need we depend, Bayesian again, formula. and we're to to us still because of continually this And TCRs X Phase of treated. the to, since science patients going are move because not a what it well,

guided by of we're a much have. And artificially with So, that and very design very think very scientifically we fact trial the supportive approved trial constrained is closely has design. also encouraging. design the not worked We're and and poor us the with forward-looking FDA that pleased I this is very

Yale Jen

great. very, for lot That's thanks the a very And again, Okay, helpful. details.

Kevin Boyle

Thanks, Yale.

Operator

from Our with next Swayampakula comes of question Ramakanth the H.C.W. line

go please Your open, is line ahead.

Swayampakula Ramakanth

Thank this Good from RK you, is Wainwright. H.C. morning, Kevin.

Kevin Boyle

Morning, RK.

Swayampakula Ramakanth

and are at of time? manufacturing as the this manufacturing reducing And for that And, experience, more you you possibility bed-to-bed? does you progress take get point, from the as of these doses, it how long seeing

Kevin Boyle

towards a Right bed-to-bed But manufacturing to there as is able development in will, reduce efforts, the Indeed vein-to-vein positively if our it. process you RK. by about half. forward is activities time, commercial that path that see we goal XX you our to now, Thanks, approximately reduce days, time, timeframe. to it's a path be called

But that's -- initiatives closely that, knows, with have be that be incremental. And we Abhi his that'll so team. that's for of up number his the and he a will development process facilitate and different Drew challenge; And will it. task he's working

the manufacturing optimize and we patient be that the of will you number the it, more refine reasons. to we get beneficial So, to days. treatment we'll quickly. will, if our naturally as One, provide reduce continue again, updates And process, for many

in manufacturing suite. Secondly, our it'll the naturally increase throughput

something it's process the updates to further let his and imagine of us, probably or much doing for at and grow how the feet, so, the we'll And about I two optimization Abhi quarter updates that going is that have in we'll we're grass not next time. under here.

Swayampakula Ramakanth

what Thanks And start Solasia that. remind relationship. they for for the an royalty you Do is last And the us idea the and have on are question and the could commercialization? when you could collaborator? between terms me second the you

Kevin Boyle

So, program, not we'll their Solasia speak to speak about. us for let to

that important to single low what's I that think I digits. is guide about wanted we're talking

not we and be on a transformational balance dollars perspective put efforts mailbox in that's from to that is assets -- just Any we released. were receive, but kind this this is that's clinical to a that So, we and use put not that message will And we'll ramp-up have dramatically our of wanted is single guidance company always something anytime alleviate it capital the that smart it's developing sheet. receive of forever. efforts, money going with in something I the them, not certainly to to to great the good -- wanted our is R&D but with work low the a been is helpful. and product the needs for and money, that given royalty capital share I our It's be to there digits, will regards terms new being that

Swayampakula Ramakanth

Perfect. good Thank And you very much. luck.

Kevin Boyle

Thank you.

Operator

of Thank Fitzgerald. follow-up Instructions] from we Cantor the line question with Agrawal you. have [Operator And a Prakhar

go ahead. open. is line Your Please

Prakhar Agrawal

thanks well. taking Hi, as follow-up the for

clarification. So, Kevin, may quick be just a

at XX time And safety days point? more is review to done second dose, Anderson the question. I MD a it first and had follow-up by move for the one at the patient, or the So, decision to later

Kevin Boyle

Sure.

somebody As wants a I appreciate when always cook, seconds.

So, good to me, sign that's a Prakhar.

any have mean much constraints on to wait if review the are our investigators But View not XX following what days daily have structural to gathering or indeed for Board window that's constraints you to that safety artificial information. of a first would the you days least the Clearly to patient basis we are wait Safety information. the number X very So, there and gather. for at

helpful. that's So, perhaps

Prakhar Agrawal

KRASGXXD versus And Kevin. or So, be in and in thanks these And it activity NEJM helpful that's Immunology similarities had TCR show the helpful, comment if and for maybe publications? TXX patient? the your between and a you can differences you can Yes, those in highlight therapy publications case Drew, maybe some recent mentioned reports if again. question would Cancer which approach Research of very

Drew Deniger

in retrovirally and mutations power case case to evidence Both these really to. are validating trial do preliminary of library of using two cells. Anderson. the showing of at really reports showing that's academic targeting cells TCR-T about MD come these in clinic We're hotspot are really some Love trying TCR-T transduce reports excited our institutions TCR-T the what we out of

think to We are very advantages. We is commercially a for we number system term. Sleeping of is think what non-viral. which are very trying that's the a long for Beauty using well-suited appealing We and there do

really And that didn't pancreatic the -- the didn't with some testing lymphodepletion about in in trial. differences because excited had of the they are And then, library regimens therapy other a patients, IL-X patient have TIL are minor high to in our dose we IL-X. do patients dose didn't our drugs may they pancreatic we previous as high respond clinical the a minor especially well there And trial. that it, received be patient received receive reminder, So, well, difference. and not both then -- use

Immunology again of those Research the looking would that I main the in, also two say TIL. guys read you TCR-T highlights paper and that. that Cancer let's are benefit differences the in-depth So, highlight encourage to over are would the but papers

thank So, you.

Kevin Boyle

And is to Sleeping TCRs TCRs, ability approach. his value paper. many and Beauty just the that's and these but Beauty, authors the one that to benefit a cost-effectively, quickly, think I at the working greatly and on be Alaunos differentiators may of we in important years that really manufacture again You with a with from here library modest, Sleeping he expertise brings

Prakhar Agrawal

next again, Thanks looking and the update. forward to

Kevin Boyle

Thanks, Prakhar.

Operator

showing Thank questions. further I And you. am no

also And question-and-answer session. and today's today's So, you conference ladies conclude gentlemen, participating. for conclude Thank does does call. this it

[Audio now may You Everyone abruptly]… ends disconnect. --

Alaunos Therapeutics (TCRT) 15 Aug 222022 Q2 Earnings call transcript